Vyome (HIND) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lexaria Bioscience is the larger company by market cap ($8.5 million vs $8.4 million), about 1.0 times the size. Lexaria Bioscience converts more of its revenue into profit, with a net margin of -1686.0% versus -3209.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | LEXX |
|---|---|---|
| Share price | $1.20 | $4.03 |
| Market cap | $8.42M | $8.49M |
| 1-day change | -17.24% | -10.24% |
| YTD return | -65.12% | — |
| 1-year return | -75.90% | — |
| 5-year return | -100.00% | — |
| P/E ratio (TTM) | 0.25 | — |
| EPS (TTM) | $4.77 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $319.71K | $705.92K |
| Revenue growth (YoY) | +24.43% | +52.05% |
| Net income (latest FY) | $-10.26M | $-11.90M |
| Gross margin | 68.43% | 99.61% |
| Operating margin | -3269.35% | -1683.01% |
| Net margin | -3209.75% | -1686.00% |
| 52-week high | $5.88 | $21.60 |
| 52-week low | $1.20 | $2.43 |
| Distance from 52-week high | -79.59% | -81.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +635.83% | +1947.15% |
| Average volume | 13.92K | 70.52K |
| Shares outstanding | 7.02M | 2.11M |
| Employees | 9 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lexaria Bioscience is more profitable, keeping -1686.0 cents of every revenue dollar as net income versus -3209.7 cents for Vyome.
- Lexaria Bioscience grew revenue faster in its latest fiscal year (+52.05% vs +24.43%).
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Lexaria Bioscience
LEXX stock →Lexaria Bioscience Corp. operates as a biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
HIND vs LEXX FAQ
Which is bigger, Vyome or Lexaria Bioscience?
Lexaria Bioscience (LEXX) is larger, with a market capitalization of $8.49M compared with $8.42M for Vyome (HIND).
Are Vyome and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.